Legislation & Regulation

AMCP comments on state legislation on substitution of interchangeable biologics.

The Academy of Managed Care Pharmacy (AMCP) thanks the Food and Drug Administration (FDA) for the opportunity to provide comments in response to the request for suggestions, recommendations and comments relevant to the FDA’s newly established Opioid Policy Steering Committee (OPSC) as published in the Federal Register on September 29, 2017.

The Academy of Managed Care Pharmacy (AMCP) appreciates the opportunity to provide information on the application of value-based contracts (VBCs) for insulin pricing initiatives. The shift in payment models is expanding beyond the delivery of health care services to encompass models of compensation between payers and biopharmaceutical manufacturers.

On November 16th, 2017, CMS released a much anticipated proposed rule that amends regulations for Medicare Part C and Medicare Part D to implement provisions of the Comprehensive Addiction and Recovery Act (CARA) and the 21st Century Cures Act. The proposed rule also makes changes to improve program quality, accessibility, and affordability and also adopts the updated NCPDP script standard for electronic prescribing.

Press Release: the Centers for Medicare and Medicaid Services (CMS) released a much anticipated proposed rule titled “Medicare Program; Contract Year 2019 Policy and Technical Changes to the Medicare Advantage, Medicare Cost Plan, Medicare Fee-for-Service, the Medicare Prescription Drug Benefit Programs, and the PACE Program.”

AMCP CEO Blog: Health care reform historically has one of the most contentious issues on Capitol Hill. The current fight to repeal the Affordable Care Act (ACA) is just the latest in a string of battles that reaches back many decades, including to the founding of Medicare and Medicaid.

AMCP CEO Blog: A recent article in The New England Journal of Medicine (NEJM) caught my attention for a couple of reasons.